Overzicht belangen werkgroepleden
Uit Richtlijnen HIV
(Verschil tussen bewerkingen)
Regel 110: | Regel 110: | ||
|- | |- | ||
| | | | ||
- | | Viiv | + | | Viiv |
- | | align="center" | x | + | | align="center" | x |
| | | | ||
| | | | ||
Regel 127: | Regel 127: | ||
| | | | ||
| Gilead | | Gilead | ||
- | | align="center" | x | + | | align="center" | x |
| | | | ||
| align="center" | x | | align="center" | x | ||
Regel 150: | Regel 150: | ||
|- | |- | ||
| | | | ||
- | | Boehringer Ingelheim<br> | + | | Boehringer Ingelheim<br> |
| | | | ||
| | | | ||
Regel 186: | Regel 186: | ||
| | | | ||
| align="center" | x | | align="center" | x | ||
- | | | + | | align="center" | x |
| | | | ||
|- | |- | ||
Regel 215: | Regel 215: | ||
| Gerrit Schreij | | Gerrit Schreij | ||
| Viiv Healthcare | | Viiv Healthcare | ||
+ | | align="center" | | ||
+ | | align="center" | | ||
| align="center" | x | | align="center" | x | ||
- | | align="center" | x | + | | align="center" | x |
- | + | ||
- | + | ||
| | | | ||
|- | |- | ||
| | | | ||
| Gilead | | Gilead | ||
- | | | + | | align="center" | |
- | | | + | | align="center" | |
| align="center" | x | | align="center" | x | ||
- | | | + | | align="center" | x |
| | | | ||
|- | |- | ||
| | | | ||
- | | | + | | Johnson en Johnson<br> |
- | | | + | | align="center" | x |
- | | | + | | align="center" | |
- | | align="center" | | + | | align="center" | |
- | | | + | | align="center" | |
| | | | ||
|- | |- | ||
| | | | ||
- | | | + | | Boehringer-Ingelheim |
- | | | + | | align="center" | |
- | | align="center" | | + | | align="center" | |
- | | align="center" | | + | | align="center" | |
- | | | + | | align="center" | |
- | | | + | | Redactioneel werk |
|- | |- | ||
| | | | ||
| MSD | | MSD | ||
- | | | + | | align="center" | |
- | | | + | | align="center" | |
| align="center" | x | | align="center" | x | ||
- | + | | align="center" | | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | | align="center" | + | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | | | + | |
| | | | ||
|} | |} |
Versie op 9 dec 2011 12:21
Naam | Firma |
Consultatie/ advisering |
Wetenschappelijk onderzoek |
Congres/ andere reis | Cursus | Anders, namelijk |
Kees Brinkman | Viiv | x | x | x | ||
BMS | x | |||||
MSD | x | x | ||||
Gilead | x | x | x | |||
Roche | x | |||||
Abbott | x | x | ||||
Jansen-Tibotec | x | x | x | |||
Mariska Tuut | Geen | |||||
Suzanne Geerlings | MSD | x | x | |||
Viiv | x | |||||
BMS | x | x | ||||
Gilead | x | x | x | Amsterdamdiner | ||
Abbott | x | |||||
Jansen Cilag (Tibotec) | x | |||||
Boehringer Ingelheim | Amsterdamdiner | |||||
Jet Gisolf | Roche | x | ||||
Merck | x | |||||
Gilead | x | x | ||||
Shering Plough | x | |||||
Abbott | x | |||||
Gerrit Schreij | Viiv Healthcare | x | x | |||
Gilead | x | x | ||||
Johnson en Johnson | x | |||||
Boehringer-Ingelheim | Redactioneel werk | |||||
MSD | x |
Door de werkgroepleden opgegeven relaties in de periode 2005-2010